

| | | |
|--|---------------------------|--|
| U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | ATTORNEY'S DOCKET NUMBER |
| TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371 | | GREGOR7 |
| | | U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 10/594080 Not Yet Assigned |
| INTERNATIONAL APPLICATION NO. | INTERNATIONAL FILING DATE | PRIORITY CLAIMED |
| PCT/IL2005/000335 | March 24, 2005 | March 24, 2004 |
| TITLE OF INVENTION | | |
| SCREENING OF ANTI-VIRAL DRUGS AND PHARMACEUTICAL COMPOSITION CONTAINING... | | |
| APPLICANT(S) FOR DO/EO/US | | |
| Paul GREGOR et al. | | |
| Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: <ol style="list-style-type: none"> <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)) as soon as the application is in order for such purpose and the applicable requirements of 35 U.S.C. 371(c) have been complied with. <input type="checkbox"/> The US has been elected (Art 31). <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> <input type="checkbox"/> is attached hereto (required only if not transmitted by the International Bureau). <input checked="" type="checkbox"/> has been communicated by the International Bureau. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> <input type="checkbox"/> is attached hereto. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). <input type="checkbox"/> have been communicated by the International Bureau. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. <input checked="" type="checkbox"/> have not been made and will not be made. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). | | |
| Items 11. to 16. below concern document(s) or information included: <ol style="list-style-type: none"> <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. <input type="checkbox"/> An Assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. <input checked="" type="checkbox"/> A FIRST preliminary amendment. <input checked="" type="checkbox"/> An Application Data Sheet under 37 CFR 1.76. <input type="checkbox"/> A substitute specification. <input type="checkbox"/> A change of power of attorney and/or address letter. <input type="checkbox"/> A computer-readable sequence form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825. <input checked="" type="checkbox"/> Other items or information: <ul style="list-style-type: none"> <input checked="" type="checkbox"/> Courtesy copy of the International Application as filed. <input checked="" type="checkbox"/> Courtesy copy of the first page of the International Publication (WO 2005/089067 A2). <input checked="" type="checkbox"/> Formal drawings, 1 sheets, Figures 1-2. <input checked="" type="checkbox"/> The application is (or will be) assigned to: Rimonyx Pharmaceuticals Ltd. whose address is P.O. Box 4056, 70400 Ness-Ziona, Israel. <input checked="" type="checkbox"/> The benefit under 35 USC §119 is claimed of the filing date of: Application No. 60/555,667 in United States on March 24, 2004, which is hereby incorporated by reference (See MPEP §201.13, pg 200-73, of revision 2, May 2004). | | |

| | | | | | |
|---|--|---|--|---|--|
| U.S. APPLICATION NO. (If known, see 37 CFR 1.5) Not 02-4035-080 | | International Application No. PCT/IL2005/000335 | | Attorney's Docket No. GREGOR7 | |
|---|--|---|--|---|--|

21. The following fees are submitted:

| | | | | | |
|--|--|--|--|----------------------------------|--|
| <input checked="" type="checkbox"/> a) BASIC NATIONAL FEE (37 CFR 1.492(a))\$300.00 <input checked="" type="checkbox"/> b) SEARCH FEE (37 CFR 1.492(b)) <input type="checkbox"/> US was International Searching Authority.....\$100.00 <input checked="" type="checkbox"/> Other ISR provided to USPTO.....\$400.00 <input type="checkbox"/> All other situations.....\$500.00 <input checked="" type="checkbox"/> c) EXAMINATION FEE (37 CFR 1.492 (c)) <input type="checkbox"/> IPEA/US gave wholly favorable IPER.....\$100.00 <input checked="" type="checkbox"/> All other situations.....\$200.00 <p style="text-align: center;">TOTAL OF ABOVE CALCULATIONS :</p> | | | | CALCULATIONS PTO USE ONLY | |
| | | | | | |

| | | | | | |
|--|--------------|---|-----------------|---------------------------|----|
| Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(h)). | | | | \$ | |
| TOTAL SHEETS | EXTRA SHEETS | Number of each additional 50 or fraction thereof (round up to a whole number) | RATE (1.492(g)) | | |
| 52 - 100 | /50 | | X \$250.00 | | |
| CLAIMS | | Number Filed | Number Extra | Rate (1.492 (d-f)) | |
| Total Claims | | 19 - 20 = | | X \$ 50.00 | \$ |
| Independent Claims | | 3 - 3 = | | X \$200.00 | \$ |
| Multiple Dependent Claims (if applicable) | | | + \$360.00 | | \$ |
| TOTAL OF ABOVE CALCULATIONS = | | | | \$600.00 | |
| Reduction of 1/2 for filing by small entity, if applicable. Applicant claims small entity status. See 37 CFR 1.27. | | | | -\$300.00 | |
| SUBTOTAL = | | | | \$300.00 | |
| Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(i)). | | | | \$ | |
| TOTAL NATIONAL FEE = | | | | \$300.00 | |
| Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property + | | | | \$ | |
| TOTAL FEES ENCLOSED = | | | | \$300.00 | |
| | | | | Amount to be: refunded | \$ |
| | | | | charged | \$ |

Payment Method (check one only)

a. ☐ A check in the amount of \$_____ to cover the above fees is enclosed.

b. ☒ Credit Card Payment Form (PTO-2038), authorizing payment in the amount of \$300.00, is attached.

c. ☐ Please charge my Deposit Account No. **02-4035** in the amount of \$_____ to cover the above fees.
A duplicate copy of this sheet is enclosed.

Handling of Fee Deficiencies (check one only)


☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. **02-4035**. A duplicate copy of this sheet is enclosed.

☐ If a deficiency exists in the basic national fee set by 37 CFR 1.492(a), please charge it to Deposit Account 02-4035. At this time, no authorization is given to charge any other fees.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

Direct all correspondence to the address associated with
CUSTOMER NUMBER 001444, which is currently:

BROWDY AND NEIMARK, P.L.L.C.
624 NINTH STREET, N.W., SUITE 300
WASHINGTON, D.C. 20001
TEL: (202) 628-5197
FAX: (202) 737-3528
 Date of this submission: **September 25, 2006**


 SIGNATURE
Roger L. Browdy
 NAME
25,618
 REGISTRATION NUMBER
 RLB:th